The objective of this study was to prioritize the most burdensome menopause symptoms among Cambodian women utilizing the best-worst scale (BWS). In total, 180 women aged 40-60 who lived in a community setting were recruited from four regions of Cambodia via convenience sampling. Using the BWS, 12 choice sets were prepared by combining 11 symptoms from the menopause rating scale (MRS), and the BWS choice sets were generated with the orthogonal main effects design (OMED). Counting approach determined the women's health priorities and calculated the best-minus-worst (BW) score. The modeling approach measured each respondent's basic utility function. Of the 180 participants, 41.1% were between the ages of 40 and 49, and 25.0% were over 50. The counting and modeling approaches revealed that heart discomfort was the most burdensome symptom (coefficient 0.739, p < .001) followed by joint and muscular discomfort (coefficient 0.606, p < .001) and sleep problems (coefficient 0.507, p < .001), whereas vaginal dryness was the least burdensome symptoms (coefficient -0.164, p = .018). This study revealed that the most burdensome menopause symptom among Cambodian women was heart discomfort while vaginal dryness was the least burdensome. The BWS enabled to prioritize the burdensome menopausal symptoms which warrants future studies using the BWS.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/03630242.2022.2068736 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Improvement in diagnostic-therapeutic care pathways for women with migraine: an Italian Delphi panel.
Front Neurol
September 2024
Department of Surgical Sciences, Women's Headache Center, University of Turin, Turin, Italy.
Background: Migraine is a highly underestimated and burdensome disease. Real-world studies evidence that migraine is more frequent and severe in women than men. However, to this day, no diagnostic-therapeutic pathways exist to satisfy the specific needs of female patients.
View Article and Find Full Text PDFEfficacy and safety of fezolinetant for vasomotor symptoms in postmenopausal women: A systematic review and meta-analysis of randomized controlled trials.
Int J Gynaecol Obstet
September 2024
Mayo Clinic, Rochester, Minnesota, USA.
Article Synopsis
- Vasomotor symptoms (VMS), including hot flashes and night sweats, are common and distressing for women undergoing menopause, and fezolinetant is being studied as a potential treatment.
- This research compiles data from six randomized controlled trials to compare the effectiveness and safety of fezolinetant against a placebo in post-menopausal women with VMS.
- Findings showed that fezolinetant significantly reduced both the frequency and severity of VMS and improved quality of life, with consistent positive results at both 4 and 12 weeks, and no notable safety concerns reported.
Counseling in menopausal women: How to address the benefits and risks of menopause hormone therapy. A FIGO position paper.
Int J Gynaecol Obstet
February 2024
FIGO Committee on Well Woman Health Care, London, UK.
Menopause marks the end of menstrual cyclicity and, depending on individual vulnerability, has several consequences related to gonadal steroid deprivation, especially if it is premature. Menopause may be more burdensome for some women than for others. Individual factors, such as personal history, socioeconomic status, ethnicity, and current health conditions, affect symptomatology and, thereby, the menopausal experience.
View Article and Find Full Text PDFThe best-worse scaling approach: prioritizing burdensome menopause symptoms among Cambodian women.
Women Health
April 2022
College of Nursing and Health Science, Texas A&M University Corpus Christi, Corpus Christi, TX 78412, USA.
The objective of this study was to prioritize the most burdensome menopause symptoms among Cambodian women utilizing the best-worst scale (BWS). In total, 180 women aged 40-60 who lived in a community setting were recruited from four regions of Cambodia via convenience sampling. Using the BWS, 12 choice sets were prepared by combining 11 symptoms from the menopause rating scale (MRS), and the BWS choice sets were generated with the orthogonal main effects design (OMED).
View Article and Find Full Text PDFAcceptability of the Dapivirine Vaginal Ring in Postmenopausal US Women.
AIDS Patient Care STDS
March 2022
Department of Medicine, Center for AIDS Prevention Studies, University of California, San Francisco, California, USA.
For women in the United States who remain sexually active beyond child-bearing years, susceptibility to HIV infection remains, yet condom use is low. We assessed acceptability of the dapivirine vaginal ring (ring) among 96 postmenopausal US women enrolled in a placebo-controlled multisite phase II trial of the ring, using questionnaires and in-depth interviews. Three quarters of women reported "perfect" adherence (ring never out) over the 3-month trial period.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!